默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价以换取特朗普政府关税豁免和政策支持_老虎社区_美港股上老虎

默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价以换取特朗普政府关税豁免和政策支持

智通财经2025-12-20

美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。特朗普政府正重启“最惠国药价”政策，试图通过行政手段压缩美国处方药的高企成本。智通财经APP获悉，根据白宫披露，已签署协议的企业包括默沙东(MRK.US)、施贵宝(BMY.US)、安进(AMGN.US)、吉利德科学(GILD.US)、葛兰素史克...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2592139231?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-20 07:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592139231","market":"hk","top_or_hot":-1,"title":"默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持","media":"智通财经","content":"<div>\n<p>美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。特朗普政府正重启“最惠国药价”政策，试图通过行政手段压缩美国处方药的高企成本。智通财经APP获悉，根据白宫披露，已签署协议的企业包括默沙东(MRK.US)、施贵宝(BMY.US)、安进(AMGN.US)、吉利德科学(GILD.US)、葛兰素史克...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1384042.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-20 07:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1384042.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。特朗普政府正重启“最惠国药价”政策，试图通过行政手段压缩美国处方药的高企成本。智通财经APP获悉，根据白宫披露，已签署协议的企业包括默沙东(MRK.US)、施贵宝(BMY.US)、安进(AMGN.US)、吉利德科学(GILD.US)、葛兰素史克...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1384042.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242646821.SGD","symbol_name":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1384042.html","article_id":"2592139231","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592139231","pubTimestamp":1766185200,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。在此次协议中，最受市场关注的是施贵宝的让利承诺。特朗普在周五的公开活动上表示，今年7月他致信要求降价的17家大型制药企业中，已有14家同意大幅下调药价。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","SG9999001176.USD":"United Global Healthcare Acc USD","BK4559":"巴菲特持仓","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4550":"红杉资本持仓","BK4588":"碎股","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","REGN":"再生元制药公司","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","GSK":"葛兰素史克","NVS":"诺华","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","GILD":"吉利德科学","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4007":"制药","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0058720904.USD":"联博国际健康护理基金A","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","BK4532":"文艺复兴科技持仓","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","BK4581":"高盛持仓","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4534":"瑞士信贷持仓","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","ROG":"罗杰斯","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","SG9999014559.SGD":"United Income Focus Trust Dis SGD","BK4516":"特朗普概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU0237698245.USD":"富达环球地产基金A","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","ABBV":"艾伯维公司","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BMY":"施贵宝","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","JNJ":"强生","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","AMGN":"安进","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0882574055.USD":"富达全球健康医疗A ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0861579265.USD":"联博低波幅策略股票基金A","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","AZN":"阿斯利康","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","MRK":"默沙东","04332":"AMGEN-T","SNY":"赛诺菲安万特","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV"},"translate_title":"Merck (MRK.US), Bristol-Myers Squibb (BMY.US) and other pharmaceutical companies agreed to lower U.S. drug prices in exchange for tariff exemptions and policy support from the Trump administration","themeId":"2acbaf8fbf691a451fa9ea170ee88816","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1.97,"AZN":1.87,"ABBV":1.86,"MRK":1.96,"SNY":1.91,"AMGN":1.92,"GSK":1.89,"04332":1.92,"ROG":1.89,"JNJ":1.87,"NVS":1.89,"GILD":1.91,"REGN":1.86},"content_text":"美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。特朗普政府正重启“最惠国药价”政策，试图通过行政手段压缩美国处方药的高企成本。智通财经APP获悉，根据白宫披露，已签署协议的企业包括默沙东(MRK.US)、施贵宝(BMY.US)、安进(AMGN.US)、吉利德科学(GILD.US)、葛兰素史克(GSK.US)、赛诺菲安万特(SNY.US)、罗杰斯(ROG.US)、Boehringer Ingelheim(勃林格殷格翰)以及诺华制药(NVS.US)等。这些公司同意在未来三年内，其产品不受特朗普政府计划对医药行业征收的专项关税影响，前提是继续加大在美国本土的生产和投资。在此次协议中，最受市场关注的是施贵宝(BMY.US)的让利承诺。该公司表示，将把其畅销抗凝血药Eliquis免费提供给美国医疗补助(Medicaid)患者。Eliquis是美国处方量最高的药物之一，此举被视为本轮降价行动中力度最大的措施之一。特朗普在周五的公开活动上表示，今年7月他致信要求降价的17家大型制药企业中，已有14家同意大幅下调药价。“这代表着美国医疗体系历史上患者可负担性方面的最大胜利，每一位美国人都将从中受益。”他同时指出，强生(JNJ.US)、艾伯维公司(ABBV.US)和再生元制药公司(REGN.US)尚未签署协议，但强生预计“下周就会加入”。尽管协议的完整条款尚未公布，白宫披露，这些药企已同意采取多项措施压低美国药价，包括以“最惠国价格”向Medicaid患者销售现有药物，并对未来新药定价作出承诺。此外，特朗普称，相关企业还将把其最受欢迎的药品上架至政府计划于明年1月推出的直销平台TrumpRx。多家企业同时宣布推出或扩大直接面向患者的销售计划。吉利德科学表示，将允许患者以折扣价获得其丙肝治疗药物Epclusa；赛诺菲称，其在感染、心血管及糖尿病领域的部分药物折扣幅度接近70%；默沙东则宣布，将通过直销项目向现金支付患者提供Januvia、Janumet和Janumet XR三款糖尿病药物，折扣约为七折，并在其在研的每日服用降胆固醇药物获批后延伸该计划。默沙东首席执行官Davis在发布会上表示，公司支持特朗普“在降低美国药价的同时，提高海外市场价格、终结全球搭便车”的政策方向。与此同时，安进宣布扩大其现有直销项目，将预防性偏头痛药物Aimovig和自身免疫治疗药物Amjevita纳入其中，月度价格折扣分别达到60%和80%。今年早些时候，特朗普政府已与礼来、诺和诺德、辉瑞、阿斯利康及EMD Serono达成类似协议，允许其以折扣价直接向患者销售部分药物，以换取关税豁免及新药审批提速等政策支持。数据显示，美国处方药价格平均几乎是海外市场的三倍，品牌药价格更是高出四倍以上。尽管行业协会PhRMA认为“最惠国定价”并非降低药价的最佳方式，并将价差归咎于药品福利管理机构，美国市场仍是全球制药企业最重要的收入来源之一，尤其是对欧洲药企而言，其对美国市场的依赖度依然居高不下。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}